Skip to Main Content
It looks like you're using Internet Explorer 11 or older. This website works best with modern browsers such as the latest versions of Chrome, Firefox, Safari, and Edge. If you continue with this browser, you may see unexpected results.

The Faculty of Medicine - Biochemistry and Molecular Biology: Lorberboum-Galski Haya


 Last updated December 2021 - Biochemistry and Molecular Biology 

List of Publications

(1) Lichtenstein M, Zabit S, Hauser N, Farouz S, Melloul O, Hirbawi J, et al. Tat for enzyme/protein delivery to restore or destroy cell activity in human diseases. Life 2021;11(9).

(2) Nitzan K, Benhamron S, Valitsky M, Kesner EE, Lichtenstein M, Ben-Zvi A, et al. Mitochondrial Transfer Ameliorates Cognitive Deficits, Neuronal Loss, and Gliosis in Alzheimer's Disease Mice. J Alzheimers Dis 2019;72(2):587-604.

(3) Erlich-Hadad T, Hadad R, Feldman A, Greif H, Lictenstein M, Lorberboum-Galski H. TAT-MTS-MCM fusion proteins reduce MMA levels and improve mitochondrial activity and liver function in MCM-deficient cells. J Cell Mol Med 2018;22(3):1601-1613.

(4) Marcus D, Lichtenstein M, Cohen N, Hadad R, Erlich-Hadad T, Greif H, et al. Heterologous mitochondrial targeting sequences can deliver functional proteins into mitochondria. Int J Biochem Cell Biol 2016;81:48-56.

(5) Kesner EE, Saada-Reich A, Lorberboum-Galski H. Characteristics of Mitochondrial Transformation into Human Cells. Sci Rep 2016;6.

(6) Sabag O, Lorberboum-Galski H. Combining flagellin and human β-defensin-3 to combat bacterial infections. Front Microbiol 2014;5(DEC).

(7) Solowey E, Lichtenstein M, Sallon S, Paavilainen H, Solowey E, Lorberboum-Galski H. Evaluating medicinal plants for anticancer activity. Sci World J 2014;2014.

(8) Marcus D, Lichtenstein M, Saada A, Lorberboum-Galski H. Replacement of the C6oRF66 assembly factor (NDUFAF4) restores complex I activity in patient cells. Mol Med 2013;19(1):124-134.

(9) Kedar R, Sabag O, Licthenstein M, Lorberboum-Galski H. Soluble CD40 ligand (sCD40L) provides a new delivery system for targeted treatment: SCD40L-caspase 3 chimeric protein for treating B-cell malignancies. Cancer 2012;118(24):6089-6104.

(10) Glantz Y, Sabag O, Lichtenstein M, Grodzovski I, Lorberboum-Galski H. Eliminating the six N-terminal amino acids of the caspase 3 large subunit improved production of a biologically active IL2-Caspase3 chimeric protein. Biotechnol Prog 2012;28(2):573-580.

(11) Israeli E, Yakunin E, Zarbiv Y, Hacohen-Solovich A, Kisos H, Loeb V, et al. α-Synuclein expression selectively affects tumorigenesis in mice modeling Parkinson's disease. PLoS ONE 2011;6(5).

(12) Lorberboum-Galski H. Human toxin-based recombinant immunotoxins/chimeric proteins as a drug delivery system for targeted treatment of human diseases. Expert Opin Drug Deliv 2011;8(5):605-621.

(13) Grodzovski I, Lichtenstein M, Galski H, Lorberboum-Galski H. IL-2-granzyme A chimeric protein overcomes multidrug resistance (MDR) through a caspase 3-independent apoptotic pathway. Int J Cancer 2011;128(8):1966-1980.

(14) Rapoport M, Salman L, Sabag O, Patel MS, Lorberboum-Galski H. Successful TAT-mediated enzyme replacement therapy in a mouse model of mitochondrial E3 deficiency. J Mol Med 2011;89(2):161-170.

(15) Eavri R, Lorberboum-Galski H. Novel approaches to the therapy of phenylketonuria. Ann Nestle 2010;68(2):70-77.

(16) Irony-Tur-Sinai M, Lichtenstein M, Brenner T, Lorberboum-Galski H. IL2-caspase3 chimeric protein controls lymphocyte reactivity by targeted apoptosis, leading to amelioration of experimental autoimmune encephalomyelitis. Int Immunopharmacol 2009;9(10):1236-1243.

(17) Shteingart S, Rapoport M, Grodzovski I, Sabag O, Lichtenstein M, Eavri R, et al. Therapeutic potency of IL2-caspase 3 targeted treatment in a murine experimental model of inflammatory bowel disease. Gut 2009;58(6):790-798.

(18) Rapoport M, Lorberboum-Galski H. TAT-based drug delivery system - New directions in protein delivery for new hopes? Expert Opin Drug Deliv 2009;6(5):453-463.

(19) Sagiv Y, Kaminitz A, Lorberboum-Galski H, Askenasy N, Yarkoni S. A fusion protein composed of IL-2 and caspase-3 ameliorates the outcome of experimental inflammatory colitis. Ann New York Acad Sci 2009;1173:791-797.

(20) Saada A, Edvardson S, Rapoport M, Shaag A, Amry K, Miller C, et al. C6ORF66 Is an Assembly Factor of Mitochondrial Complex I. Am J Hum Genet 2008;82(1):32-38.

(21) Rapoport M, Saada A, Elpeleg O, Lorberboum-Galski H. TAT-mediated delivery of LAD restores pyruvate dehydrogenase complex activity in the mitochondria of patients with LAD deficiency. Mol Ther 2008;16(4):691-697.

(22) Eavri R, Lorberboum-Galski H. A novel approach for enzyme replacement therapy: The use of phenylalanine hydroxylase-based fusion proteins for the treatment of phenylketonuria. J Biol Chem 2007;282(32):23402-23409.

(23) Segel MJ, Aqeilan K, Zilka K, Lorberboum-Galski H, Wallach-Dayan SB, Conner MW, et al. Effect of IL-2-Bax, a novel interleukin-2-receptor-targeted chimeric protein, on bleomycin lung injury. Int J Exp Pathol 2005;86(5):279-288.

(24) Lichtenstein M, Ben-Yehudah A, Belostotsky R, Eaveri R, Sabag O, Grodzovski I, et al. Utilizing a GnRH-based chimeric protein for the detection of adenocarcinoma. Int J Oncol 2005;27(1):143-148.

(25) Eaveri R, Ben-Yehudah A, Lorberboum-Galski H. Surface antigens/receptors for targeted cancer treatment: The GnRH receptor/binding site for targeted adenocarcinoma therapy. Curr Cancer Drug Targets 2004;4(8):673-687.

(26) Ben-Yehudah A, Lorberboum-Galski H. Targeted cancer therapy with gonadotropin-releasing hormone chimeric proteins. Expert Rev Anticancer Ther 2004;4(1):151-161.

(27) Belostotsky R, Lorberboum-Galski H. Utilizing Fcε-Bak chimeric protein for studying IgE-FcεRI interactions. Clin Immunol 2004;110(1):89-99.

(28) Ben-Yehudah A, Aqeilan R, Robashkevich D, Lorberboum-Galski H. Using apoptosis for targeted cancer therapy by a new gonadotropin releasing hormone-DNA fragmentation factor 40 chimeric protein. Clin Cancer Res 2003;9(3):1179-1190.

(29) Aqeilan R, Kedar R, Ben-Yehudah A, Lorberboum-Galski H. Mechanism of action of interleukin-2 (IL-2)-Bax, an apoptosis-inducing chimaeric protein targeted against cells expressing the IL-2 receptor. Biochem J 2003;370(1):129-140.

(30) Malamud V, Vaaknin A, Abramsky O, Mor M, Burgess LE, Ben-Yehudah A, et al. Tryptase activates peripheral blood mononuclear cells causing the synthesis and release of TNF-α, IL-6 and IL-1β: Possible relevance to multiple sclerosis. J Neuroimmunol 2003;138(1-2):115-122.

(31) Ben-Yehudah A, Belostotsky R, Lichtenstein M, Aqeilan R, Abady R, Lorberboum-Galski H. Chimeric proteins as candidates for cancer treatment. Drugs Future 2002;27(9):851-861.

(32) Ben-Yehudah A, Aqeilan R, Belostotsky R, Azar Y, Lorberboum-Galski H. Utilizing chimeric proteins for exploring the cellular fate of endogenous proteins. Biochem Biophys Res Commun 2002;290(1):332-338.

(33) Belostotsky R, Lorberboum-Galski H. Apoptosis-inducing human-origin Fcε-Bak chimeric proteins for targeted elimination of mast cells and basophils: A new approach for allergy treatment. J Immunol 2001;167(8):4719-4728.

(34) Ben-Yehudah A, Prus D, Lorberboum-Galski H. I.V. administration of L-GnRH-PE66 efficiently inhibits growth of colon adenocarcinoma xenografts in nude mice. Int J Cancer 2001;92(2):263-268.

(35) Azar Y, Lorberboum-Galski H. GnRH-Bik/Bax/Bak chimeric proteins target and kill adenocarcinoma cells; the general use of pro-apoptotic proteins of the Bcl-2 family as novel killing components of targeting chimeric proteins. Apoptosis 2000;5(6):531-542.

(36) Fishman A, Prus D, Belostotsky R, Lorberboum-Galski H. Targeted Fc(2'-3)-PE40 chimeric protein abolishes passive cutaneous anaphylaxis in mice. Clin Exp Immunol 2000;119(3):398-403.

(37) Aqeilan R, Yarkoni S, Lorberboum-Galski H. Interleukin 2-Bax: A novel prototype of human chimeric proteins for targeted therapy. FEBS Lett 1999;457(2):271-276.

(38) Brenner T, Steinberger I, Soffer D, Beraud E, Ben-Nun A, Lorberboum-Galski H. A novel antigen-toxin chimeric protein: Myelin-basic protein- pseudomonas exotoxin (MBP-PE 40) for treatment of experimental autoimmune encephalomyelitis. Immunol Lett 1999;68(2-3):403-410.

(39) Ben-Yehudah A, Yarkoni S, Nechushtan A, Belostotsky R, Lorberboum-Galski H. Linker-based GnRHh-PE chimeric proteins inhibit cancer growth in nude mice. Med Oncol 1999;16(1):38-45.

(40) Nechushtan A, Yarkoni S, Marianovsky I, Lorberboum-Galski H. Adenocarcinoma cells are targeted by the new GnRH-PE66 chimeric toxin through specific gonadotropin-releasing hormone binding sites. J Biol Chem 1997;272(17):11597-11603.

(41) Fishman A, Lorberboum-Galski H. Targeted elimination of cells expressing the high-affinity receptor for IgE (FcεRI) by a Pseudomonas exotoxin-based chimeric protein. Eur J Immunol 1997;27(2):486-494.

(42) Steinberger I, Ben-Bassat H, Hochberg E, Lorberboum-Galski H. Interleukin-2 (IL-2) receptor α, β and γ subunit expression as a function of B-cell lineage ontogeny: The use of IL-2-PE66(4Glu) to characterize internalization via IL-2 receptor subunits. Scand J Immunol 1997;46(2):129-136.

(43) Yarkoni S, Lishner M, Tangi I, Nagler A, Lorberboum-Galski H. B-cell non-Hodgkin's lymphoma: Evidence for the t(14; 18) translocation in all hematopoietic cell lineages. J Natl Cancer Inst 1996;88(14):973-979.

(44) Steinberger I, Brenner T, Lorberboum-Galski H. Interleukin 2 pseudomonas exotoxin (IL2-PE664Glu) chimeric protein kills B cells from patients with myasthenia gravis. Cell Immunol 1996;169(1):55-61.

(45) Benezra D, Maftzir G, Hochberg E, Anteby I, Lorberboum-Galski H. Ocular distribution of the chimeric protein IL2-PE40. Curr Eye Res 1995;14(2):153-158.

(46) Steinberger I, Brenner T, Lorberboum-Galski H. Interleukin-2 Pseudomonas exotoxin chimeric protein is cytotoxic to B cell cultures derived from myasthenia gravis patients. J Neurol Sci 1995;133(1-2):183-191.

(47) Lorberboum-Galski H, Yarkoni S, Nechushtan A, Rachmilewitz J, De Groot N, Hochberg A. ABL and BCR Genes are not imprinted in androgenetic and gynogenetic human tissues. Biochem Biophys Res Commun 1994;204(2):621-627.

(48) Fishman A, Bar-Kana Y, Steinberger I, Lorberboum-Galski H. Increased Cytotoxicity of Interleukin 2-Pseudomonas Exotoxin (IL2-PE) Chimeric Proteins Containing a Targeting Signal for Lysosomal Membranes. Biochemistry 1994;33(20):6235-6243.

(49) Lorberboum-Galski H. Interleukin 2-pseudomonas exotoxin a (IL2-PE40) chimeric protein for targeted immunotherapy and the study of immune responses. Toxin Rev 1994;13(1):105-109.

(50) Amiel A, Yarkoni S, Slavin S, Or R, Lorberboum-Galski H, Fejgin M, et al. Detection of minimal residual disease state in chronic myelogenous leukemia patients using fluorescence in situ hybridization. Cancer Genet Cytogenet 1994;76(1):59-64.

(51) Volk H-, Muller S, Yarkoni S, Diamantstein T, Lorberboum-Galski H. Mechanisms of dichotomous action of IL-2-pseudomonas exotoxin 40 (IL-2- PE40) on cell-mediated and humoral immune response. J Immunol 1994;153(6):2497-2505.

(52) Beraud E, Lorberboum-Galski H, Chan CC, FitzGerald D, Pastan I, Nussenblatt RB. Immunospecific suppression of encephalitogenic-activated T lymphocytes by chimeric cytotoxin IL-2-PE40. Cell Immunol 1991;133(2):379-389.

(53) Herbort CP, de Smet MD, Roberge FG, Nussenblatt RB, Fitzgerald D, Lorberboum-Galski H, et al. Treatment of corneal allograft rejection with the cytotoxin IL-2-PE40. Transplantation 1991;52(3):470-474.

(54) Lorberboum-Galski H, Lafyatis R, Case JP, FitzGerald D, Wilder RL, Pastan I. Administration of IL-2-PE40 via osmotic pumps prevents adjuvant induced arthritis in rats. Improved therapeutic index of IL-2-PE40 administered by continuous infusion. Int J Immunopharmacol 1991;13(2-3):305-315.

(55) Rose JW, Lorberboum-Galski H, Fitzgerald D, McCarron R, Hill KE, Townsend JJ, et al. Chimeric cytotoxin IL2-PE40 inhibits relapsing experimental allergic encephalomyelitis. J Neuroimmunol 1991;32(3):209-217.

(56) Lorberboum-Galski H, Garsia RJ, Gately M, Brown PS, Clark RE, Waldmann TA, et al. IL2-PE66(4Glu), a new chimeric protein cytotoxic to human-activated T lymphocytes. J Biol Chem 1990;265(27):16311-16317.

(57) Kozak RW, Lorberboum-Galski H, Jones L, Puri RK, Willingham MC, Malek T, et al. IL-2-PE40 prevents the development of tumors in mice injected with IL-2 receptor expressing EL4 transfectant tumor cells. J Immunol 1990;145(8):2766-2771.

(58) Lorberboum-Galski H, Barrett LV, Kirkman RL, Ogata M, Willingham MC, FitzGerald DJ, et al. Cardiac allograft survival in mice treated with IL-2-PE40. Proc Natl Acad Sci U S A 1989;86(3):1008-1012.

(59) Roberge FG, Lorberboum-Galski H, Le Hoang P, De Smet M, Chan CC, Fitzgerald D, et al. Selective immunosuppression of activated T cells with the chimeric toxin IL-2-PE40. Inhibition of experimental autoimmune uveoretinitis. J Immunol 1989;143(11):3498-3502.

(60) Case JP, Lorberboum-Galski H, Lafyatis R, FitzGerald D, Wilder RL, Pastan I. Chimeric cytotoxin IL2-PE40 delays and mitigates adjuvant-induced arthritis in rats. Proc Natl Acad Sci U S A 1989;86(1):287-291.

(61) Ogata M, Lorberboum-Galski H, Fitzgerald D, Pastan I. IL-2-PE40 is cytotoxic for activated T lymphocytes expressing IL-2 receptors. J Immunol 1988;141(12):4224-4228.

(62) Lorberboum-Galski H, Kozak RW, Waldmann TA, Bailon P, FitzGerald DJP, Pastan I. Interleukin 2 (IL2) PE40 is cytotoxic to cells displaying either the p55 or p70 subunit of the IL2 receptor. J Biol Chem 1988;263(35):18650-18656.

(63) Lorberboum-Galski H, FitzGerald D, Chaudhary V, Adhya S, Pastan I. Cytotoxic activity of an interleukin 2-Pseudomonas exotoxin chimeric protein produced in Escherichia coli. Proc Natl Acad Sci U S A 1988;85(6):1922-1926.

(64) Ballon P, Weber DV, Gately M, Smart JE, Lorberboum-Galski H, Fitzgerald D, et al. Purification and partial characterization of an interleukin 2-pseudomonas exotoxin fusion protein. Biotechnology 1988;6(11):1326-1329.

(65) KLOPPSTECH K, LORBERBOUM H, DE GROOT N, HOCHBERG AA. Translational control at the level of initiation between mRNAs for pre‐existing proteins and a 22‐kDa heat‐shock protein of Chlamydomonas by small cytosolic RNAs. Eur J Biochem 1987;167(3):501-505.

(66) Lorberboum H, Galski H, Scharf C, Weinstein D, de Groot N, Hochberg AA. Alkaline phosphatase and protein kinase(s) activities in free cytoplasmic mRNPs from human term placenta. Mol Biol Rep 1986;11(1):29-35.

(67) LORBERBOUM H, DIGWEED M, ERDMANN VA, SERVADIO Y, WEINSTEIN D, GROOT ND, et al. Small cytoplasmic RNAs from human placental free mRNPs: Structure and their effect on in vitro protein synthesis. Eur J Biochem 1986;155(2):279-287.

(68) Gileadi O, Lorberboum H, de Groot N, Hochberg AA. Location of RNase and RNase inhibitor on free cytoplasmic mRNA-protein particles from human placenta. Mol Biol Rep 1984;9(4):241-244.

(69) Lorberboum H, Schneider T, de Groot N, Hochberg AA. The effect of protein and RNA synthesis inhibitors on the synthesis and secretion of hCG, α- and β-hCG subunits, in organ culture. Eur J Obstet Gynecol Reprod Biol 1984;18(1-2):57-69.

(70) Lorberboum H, Weinstein D, Galski H, de Groot N, Segal S, Ilan J, et al. RNA synthesis in cultured human placenta. Mol Biol Rep 1982;8(2):103-110.

(71) Lorberboum H, Weinstein D, De Groot N, Hochberg AA. Messenger ribonucleoprotein particles in human term placenta. Biochem Int 1982;5(3):407-414.

(72) Weinstein D, Galski H, Schenker JG, Lorberboum H, Groot Nd, Ilan J, et al. The synthesis and secretion of human placental lactogen (hPL) in cultured term placenta. Mol Cell Endocrinol 1982;26(1-2):189-199.